AIM2 and chronic obstructive pulmonary disease: Starting from the above published data, we found that PBMCs obtained from exacerbated, but not stable, COPD patients were more responsive to AIM2 activation regardless of corticosteroid treatment, implying that AIM2 plays a role during the exacerbation phase of COPD.